Skip to contentA
Aclaris Therapeutics, Inc.
A
ACRSAclaris Therapeutics, Inc. Q2 2022 · 10-Q
Revenue$1.53M$1.53M−16.2% vs Q2 2021 Net Income-$20.53M-$20.53MN/M vs Q2 2021 EPS Diluted-$0.31-$0.31N/M vs Q2 2021 Operating Income-$20,994,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aclaris Therapeutics, Inc. · CIK 1557746 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$19,852,000— Margins · derivedOperating margin-1374.0%−386.8 pt vs Q2 2021
Net margin-1343.7%−348.0 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 3, 2022 · 34 d after period end